*12-month plan · save $240/yr · flat rate across full 0.25–2.4 mg titration. $147 (6-mo, save $108) · $149 (3-mo, save $48) · $165 (monthly).
Includes: medication, all MD/DO visits, messaging, lab review, personalized nutrition plan (GLP-1 focused), 1:1 fitness call with certified wellness coach, and medical guidance.
Compounded only — no brand-name Wegovy® / Ozempic® / Rybelsus®. Cash-pay with HSA/FSA only — no in-network insurance billing. Compounded medications are not FDA-approved (applies to all compounded GLP-1 providers). Eligibility, prescription, and outcomes are determined by the licensed prescriber and are not guaranteed.
Compounded only — no brand-name Wegovy® / Zepbound®. Cash-pay with HSA/FSA only — no in-network insurance billing. Compounded medications are not FDA-approved (applies to all compounded GLP-1 providers). Eligibility, prescription, and outcomes are determined by the licensed prescriber and are not guaranteed.
Pivotal clinical trials
Below: every randomized trial relevant to semaglutide weight management, type 2 diabetes, cardiovascular outcomes, and kidney outcomes. PMIDs link to PubMed.
STEP-1 trial — Pivotal weight-loss in non-diabetic adults. NEJM 2021, n=1,961, PMID 33567185. 14.9% mean weight loss at 2.4 mg / 68 weeks.
SUSTAIN-6 trial — Cardiovascular safety in type 2 diabetes. NEJM 2016, PMID 27633186. 26% MACE reduction in T2D + high CV risk.
SELECT trial — CV outcomes in non-diabetic adults with overweight/obesity + CVD. NEJM 2023, PMID 37952131. 20% MACE reduction.
FLOW trial — Kidney outcomes in T2D + CKD. NEJM 2024, PMID 38785189. 24% reduction in major kidney/CV events.
Mechanism & pharmacology
Semaglutide is a long-acting GLP-1 receptor agonist with ~7-day half-life enabling weekly subcutaneous dosing. Read the mechanism page →
Safety & contraindications
Boxed warning: thyroid C-cell tumors (rodent studies). Contraindicated in MTC, MEN 2, pregnancy, breastfeeding. Full safety page →
